AXL upregulation is associated with aggressive and drug‐resistant RCC and is regarded as a poor prognosis marker (Gay et al., 2017; Yu et al., 2015; Zucca et al., 2018), thus identifying this protein as a potential target of anticancer therapy. Here, AXL is linked to renal cell adenocarcinoma.